Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2025-08-04 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于自愿披露全资子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding its wholly-owned subsidiary obtaining medical device registration certificates. It includes details about the certificates, product information, impact on the company, and risk warnings. The document is short (1234 characters) and is an announcement of a specific event rather than a financial report or detailed regulatory filing. It does not contain financial statements, management discussion, or audit information. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best with a general regulatory announcement about a corporate event, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2025-08-04 Chinese
江苏浩欧博生物医药股份有限公司关于出售土地使用权、厂房建筑物的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the sale of land use rights and factory buildings. It details the transaction terms, board approval, buyer information, asset valuation, contract terms, and impact on the company. The document is a formal announcement of a specific capital asset sale transaction, including financial details and board resolutions. It is not a full financial report, audit report, or earnings release. It is not a regulatory filing or report publication announcement since it contains substantive transaction details and approvals. The content fits best under Capital/Financing Update (CAP) as it relates to a significant asset sale and capital structure change. Confidence is high given the detailed transaction and board approval information.
2025-08-04 Chinese
江苏浩欧博生物医药股份有限公司2023年限制性股票激励计划首次授予部分第二类激励对象第一个归属期归属结果暨股票上市公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the listing and vesting results of restricted stock under a 2023 stock incentive plan by Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the decision-making process, the number of shares vested, the listing date, shareholding changes, and the impact on earnings per share. The document includes meeting dates, approvals, and regulatory compliance references but does not contain full financial statements or detailed financial performance data. The length is 4267 characters, which is relatively short and the document primarily serves as an official announcement of stock incentive vesting and listing rather than a full report. Therefore, it fits best as a Regulatory Filing (RNS) because it is a formal disclosure of share issuance and stock incentive plan progress without being a full financial report or a capital/financing update focused on fundraising. It is not a Capital/Financing Update (CAP) because it does not discuss new fundraising or capital structure changes beyond the stock incentive issuance, which is more administrative and compliance-related. Hence, the classification is Regulatory Filings (RNS) with high confidence.
2025-06-30 Chinese
江苏浩欧博生物医药股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Jiangsu Haoubo Biopharmaceutical Co., Ltd. regarding abnormal stock price fluctuations over three consecutive trading days. It includes details about the stock price changes, company self-inspection results, confirmation that no undisclosed material information exists, and risk warnings to investors. The document references stock trading rules and regulatory requirements but does not contain financial statements or detailed financial data. It is a regulatory announcement about stock price behavior and company disclosures, not a financial report or earnings release. The document length is 2057 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-06-12 Chinese
《关于江苏浩欧博生物医药股份有限公司股票交易异常波动的询证函》的回函
Regulatory Filings Classification · 95% confidence The document is a formal response letter from controlling shareholders and actual controllers to an inquiry about abnormal stock trading fluctuations. It explicitly states that no undisclosed major information exists that could affect stock price and denies any trading activity during the abnormal fluctuation period. The document is short (810 characters) and serves as a regulatory response to a stock trading inquiry rather than a financial report or announcement of a meeting or vote. It does not contain financial data, management changes, or legal proceedings. This fits best under Regulatory Filings (RNS), which covers miscellaneous compliance and regulatory announcements that do not fit other categories.
2025-06-12 Chinese
国浩律师（上海）事务所关于江苏浩欧博生物医药股份有限公司2023年限制性股票激励计划授予价格调整相关事项之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the grant price for a 2023 restricted stock incentive plan of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It contains detailed legal analysis, references to company board and shareholder meetings, regulatory compliance, and the legal basis for the price adjustment. The document is not a financial report, earnings release, or management discussion, but a standalone legal opinion related to a specific corporate action (stock incentive plan price adjustment). It is not an announcement of a report publication but the actual legal opinion document. This fits best under the category of Audit Report / Information (AR), as it is a standalone legal/audit-related report concerning compliance and regulatory matters related to the stock incentive plan. The document length (6779 characters) supports it being a full report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2024
2025-06-11 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.